Trials / Unknown
UnknownNCT02851589
Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Industry
- Sex
- All
- Age
- 14 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with CD19 positive relapsed or refractory Leukemia and Lymphoma.
Conditions
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Follicular Lymphoma
- Mantle Cell Lymphoma
- B-cell Prolymphocytic Leukemia
- Diffuse Large Cell Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PCAR-019 (anti-CD19 CAR-T cells) |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2018-11-01
- Completion
- 2019-11-01
- First posted
- 2016-08-01
- Last updated
- 2016-08-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02851589. Inclusion in this directory is not an endorsement.